Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Luteolin-loaded Phytosomes Sensitize Human Breast Carcinoma MDA-MB 231 Cells to Doxorubicin by Suppressing Nrf2 Mediated Signalling

  • Sabzichi, Mehdi (Department of Biochemistry and Clinical Laboratory, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Hamishehkar, Hamed (Drug Applied Research Center, Tabriz University of Medical Sciences) ;
  • Ramezani, Fatemeh (Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences) ;
  • Sharifi, Simin (Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences) ;
  • Tabasinezhad, Maryam (Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences) ;
  • Pirouzpanah, Mohammadbagher (Department of Biochemistry and Clinical Laboratory, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Ghanbari, Parisa (Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences) ;
  • Samadi, Nasser (Department of Biochemistry and Clinical Laboratory, Faculty of Medicine, Tabriz University of Medical Sciences)
  • Published : 2014.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Nuclear factor erythroid 2-related factor 2 (Nrf2) has been recognized as a transcription factor that controls mechanisms of cellular defense response by regulation of three classes of genes, including endogenous antioxidants, phase II detoxifying enzymes and transporters. Previous studies have revealed roles of Nrf2 in resistance to chemotherapeutic agents and high level expression of Nrf2 has been found in many types of cancer. At physiological concentrations, luteolin as a flavonoid compound can inhibit Nrf2 and sensitize cancer cells to chemotherapeutic agents. We reported luteolin loaded in phytosomes as an advanced nanoparticle carrier sensitized MDA-MB 231 cells to doxorubicin. In this study, we prepared nano phytosomes of luteolin to enhance the bioavailability of luteolin and improve passive targeting in breast cancer cells. Our results showed that cotreatment of cells with nano particles containing luteolin and doxorubicin resulted in the highest percentage cell death in MDA-MB 231cells (p<0.05). Furthermore, luteolin-loaded nanoparticles reduced Nrf2 gene expression at the mRNA level in cells to a greater extent than luteolin alone (p<0.05). Similarly, expression of downstream genes for Nrf2 including Ho1 and MDR1 were reduced significantly (p<0.05). Inhibition of Nrf-2 expression caused a marked increase in cancer cell death (p<0.05). Taken together, these results suggest that phytosome technology can improve the efficacy of chemotherapy by overcoming resistance and enhancing permeability of cancer cells to chemical agents and may thus be considered as a potential delivery system to improve therapeutic protocols for cancer patients.

Keywords

References

  1. Agarwal A, Chakraborty P, Chakraborty DD, et al (2012). Phytosomes: complexation, Utilisation and Commerical Status. J Biol Active Prod from Nature, 2, 65-77. https://doi.org/10.1080/22311866.2012.10719111
  2. Akan Z, Garip AI (2013). Antioxidants may protect cancer cells from apoptosis signals and enhance cell viability. Asian Pac J Cancer Prev, 14, 4611-4. https://doi.org/10.7314/APJCP.2013.14.8.4611
  3. Bhattacharya S, Ghosh AK, (2009). Phytosomes: the emerging technology for enhancement of bioavailability of botanicals and nutraceuticals. Int J Aesthetic & Antiaging Med, 2, 1.
  4. Chian S, Li YY, Wang XJ, Tang XW (2014). Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the nrf2 pathway. Asian Pac J Cancer Prev, 15, 2911. https://doi.org/10.7314/APJCP.2014.15.6.2911
  5. Crunkhorn S (2012). Deal watch: abbott boosts investment in NRF2 activators for reducing oxidative stress. Nature Rev Drug Discov, 11, 96-6. https://doi.org/10.1038/nrd3655
  6. Di Pierro F1, Menghi AB, Barreca A, Lucarelli M, Calandrelli A (2009). Greenselect Phytosome as an adjunct to a low-calorie diet for treatment of obesity: a clinical trial. Altern Med Rev, 14, 154-60.
  7. Freag MS, Elnaggar YS, Abdallah OY (2013). Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomedicine, 8, 2385-97.
  8. Gao AM, Ke ZP, Shi F, Sun GC, Chen H (2013). Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact, 206, 100-8. https://doi.org/10.1016/j.cbi.2013.08.008
  9. George VC, Naveen Kumar DR, Suresh PK, Kumar S, Kumar RA (2013). Comparative studies to evaluate relative in vitro potency of luteolin in inducing cell cycle arrest and apoptosis in HaCaT and A375 cells. Asian Pac J Cancer Prev, 14, 631-7. https://doi.org/10.7314/APJCP.2013.14.2.631
  10. Hart P, Minshall R, Bonini M, et al. (2014). Caveolin-1-dependent regulation of cellular metabolism in breast cancer: role of Nrf-2 and MnSOD (693.19). FASEB J, 693, 19.
  11. Hu XF, Yao J, Gao SG, et al (2013). Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. Asian Pac J Cancer Prev, 14, 5231-5. https://doi.org/10.7314/APJCP.2013.14.9.5231
  12. Hwang JT, Park OJ, Lee YK, et al (2011). Anti-tumor effect of luteolin is accompanied by AMP-activated protein kinase and nuclear factor-$I^{\circ}B$ modulation in HepG2 hepatocarcinoma cells. Int J Mol Med, 28, 25-31.
  13. Khunluck T, Kukongviriyapan V, Puapairoj A, et al (2014). Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients. Asian Pac J Cancer Prev, 15, 299-304. https://doi.org/10.7314/APJCP.2014.15.1.299
  14. Kweon MH, Adhami VM, Lee JS, Mukhtar H (2006). Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem, 281, 33761-72. https://doi.org/10.1074/jbc.M604748200
  15. Li Y, Paonessa JD, Zhang Y (2012). Mechanism of chemical activation of Nrf2. PloS One, 7, 35122. https://doi.org/10.1371/journal.pone.0035122
  16. Lopez-Lazaro M (2009). Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem, 9, 31-59. https://doi.org/10.2174/138955709787001712
  17. Manthena S, Srinivas P (2010). Phytosomes in herbal drug delivery. J Natural Pharmaceuticals, 1, 14. https://doi.org/10.4103/2229-5119.73581
  18. Mathur M (2013). Phyto-complex and their role in enhancing efficacy of herbal drugs. MPIJPRI, 5, 118-25.
  19. Mukherjee K, Maiti K, Venkatesh M, Mukherjee PK (2008). Phytosome of hesperetin, a value added formulation with phytomolecules. 60th Indian Pharmaceutical Congress; 2008 Dec 12-14; New Delhi, India. p. 287.
  20. Pandurangan AK, Dharmalingam P, Ananda Sadagopan SK, Ganapasam S (2012). Effect of luteolin on the levels of glycoproteins during azoxymethane-induced colon carcinogenesis in mice. Asian Pac J Cancer Prev, 13, 1569-73. https://doi.org/10.7314/APJCP.2012.13.4.1569
  21. Ren D, Villeneuve NF, Jiang T (2011). Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci USA, 108, 1433-8. https://doi.org/10.1073/pnas.1014275108
  22. Samadi N, Bekele RT, Goping IS, Schang LM, Brindley DN (2011). Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PloS one, 6, e20608. https://doi.org/10.1371/journal.pone.0020608
  23. Samadi N, Gaetano C, Goping IS, Brindley DN (2009). Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene, 28, 1028-39. https://doi.org/10.1038/onc.2008.442
  24. Shen H, Zhou S, Wang J (2013). The paradoxical role of Nrf2 in tumor biology. Crit Rev Eukaryot Gene Expr, 23, 37-47. https://doi.org/10.1615/CritRevEukarGeneExpr.2013006288
  25. Suryawanshi S (2011). Phytosome: an emerging trend in herbal drug treatment. J Med Gene Geno, 3, 109-14.
  26. Tabasinezhad M, Samadi N1, Ghanbari P, et al (2013). Sphingosin 1-phosphate contributes in tumor progression. J Cancer Res Ther, 9, 556-63. https://doi.org/10.4103/0973-1482.126446
  27. Tang JC1, Shi HS, Wan LQ, Wang YS, Wei YQ (2013). Enhanced antitumor effect of curcumin liposomes with local hyperthermia in the LL/2 model. Asian Pac J Cancer Prev, 14, 2307-10. https://doi.org/10.7314/APJCP.2013.14.4.2307
  28. Tang X, Wang H, Fan L (2011). Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med, 50, 1599-609. https://doi.org/10.1016/j.freeradbiomed.2011.03.008
  29. Xu K1, Liu B, Ma Y (2009). Physicochemical properties and antioxidant activities of luteolin-phospholipid complex. Molecules, 14, 3486-93. https://doi.org/10.3390/molecules14093486
  30. Zhao Y, Yang G, Ren D (2011). Luteolin suppresses growth and migration of human lung cancer cells. Mol Biol Rep, 38, 1115-9. https://doi.org/10.1007/s11033-010-0208-x
  31. Zhu CY1, Lv YP, Yan DF, Gao FL (2013). Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells. Asian Pac J Cancer Prev, 14, 6757-60. https://doi.org/10.7314/APJCP.2013.14.11.6757
  32. Zucker SN, Fink EE, Bagati A (2014). Nrf2 amplifies oxidative stress via induction of Klf9. Mol cell, 53, 916-28. https://doi.org/10.1016/j.molcel.2014.01.033

Cited by

  1. Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5191
  2. Silibilin-Induces Apoptosis in Breast Cancer Cells by Modulating p53, p21, Bak and Bcl-xl Pathways vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2087
  3. Skin Redox Balance Maintenance: The Need for an Nrf2-Activator Delivery System vol.3, pp.1, 2016, https://doi.org/10.3390/cosmetics3010001
  4. Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells vol.43, pp.2, 2016, https://doi.org/10.1007/s11033-016-3942-x